EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EYPT | EyePoint Pharmaceuticals, Inc. | 2025-10-16 17:28:36 | 11.65 | 0.1 | 0.87 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EYPT | 0001314102 | EyePoint Pharmaceuticals, Inc. | US30233G2093 | 549300QE1RU34T50MR69 | 262774444 | Nasdaq | 3826 | Laboratory Analytical Instruments | 1231 | DE | 480 PLEASANT STREET | WATERTOWN | MA | 02472 | UNITED STATES | US | 617-926-5000 | 480 PLEASANT STREET, WATERTOWN, MA, 02472 | 480 PLEASANT STREET, WATERTOWN, MA, 02472 | pSivida Corp. | Pharmaceuticals | — | — | — | http://www.psivida.com | 450,800,000 | 68,889,649 | 68,927,425 | EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery. | 2025-10-10 21:15:20 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 450,800,000 | 217,900,000 | 93.5595 | 68,728,760 | 18,897,968 | 37.9243 |
| 2023 | 232,900,000 | 23,389,613 | 11.1639 | 49,830,792 | 15,528,866 | 45.2711 |
| 2022 | 209,510,387 | 17,093,443 | 8.8835 | 34,301,926 | 257,671 | 0.7569 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ramiro Ribeiro | Chief Medical Officer | 2024 | 404,167 | 60,000 | 0 | 276,359 | 2,052 | 3,533,919 |
| George Elston | Chief Financial Officer, Executive Vice President | 2024 | 507,368 | 0 | 918,000 | 291,917 | 25,189 | 3,204,973 |
| Jay Duker | Chief Executive Officer, President | 2024 | 669,500 | 0 | 1,836,000 | 498,888 | 25,421 | 5,954,807 |
| Nancy Lurker | Chair, Chief Executive Officer, President, Director | 2023 | 570,025 | 49,242 | 1,038,477 | 574,486 | 25,527 | 3,737,385 |
| George Elston | Chief Financial Officer, Executive Vice President | 2023 | 487,824 | 24,938 | 282,912 | 367,141 | 25,441 | 1,780,125 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 165 |
| 2023 | 121 |
| 2022 | 144 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 43,273,000 | 46,018,000 | 41,404,000 |
| Cost Of Revenue | 3,712,000 | 4,632,000 | 8,326,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 132,926,000 | 64,662,000 | 49,642,000 |
| General And Administrative Expenses | 52,358,000 | 40,102,000 | 34,817,000 |
| Operating Expenses | 189,127,000 | 121,085,000 | 141,041,000 |
| Operating Income | -145,854,000 | -75,067,000 | -99,637,000 |
| Net Income | -130,870,000 | -70,795,000 | -102,254,000 |
| Earnings Per Share Basic | -2.32 | -1.82 | -2.74 |
| Earnings Per Share Diluted | -2.32 | -1.82 | -2.74 |
| Weighted Average Shares Outstanding Basic | 56,298 | 38,904,000 | 37,317,000 |
| Weighted Average Shares Outstanding Diluted | 56,298 | 38,904,000 | 37,317,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 99,704,000 | 281,263,000 | 95,633,000 |
| Marketable Securities Current | 271,209,000 | 49,787,000 | 48,928,000 |
| Accounts Receivable | 607,000 | 805,000 | 15,503,000 |
| Inventories | 2,305,000 | 3,906,000 | 2,886,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,405,000 | 1,009,000 | 782,000 |
| Total Assets Current | 383,306,000 | 344,800,000 | 172,808,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 8,177,000 | 5,251,000 | 1,360,000 |
| Other Assets Non Current | 5,832,000 | — | — |
| Total Assets Non Current | 35,159,000 | 10,384,000 | 7,548,000 |
| Total Assets | 418,465,000 | 355,184,000 | 180,356,000 |
| Accounts Payable | 11,721,000 | 6,504,000 | 5,919,000 |
| Deferred Revenue | 17,784,000 | 38,592,000 | 1,205,000 |
| Short Term Debt | — | 0 | 10,475,000 |
| Other Liabilities Current | 1,440,000 | 646,000 | 579,000 |
| Total Liabilities Current | 49,048,000 | 63,263,000 | 34,537,000 |
| Long Term Debt | — | — | 30,000,000 |
| Other Liabilities Non Current | 205,000 | — | 600,000 |
| Total Liabilities Non Current | 32,916,000 | 25,598,000 | 49,451,000 |
| Total Liabilities | 81,964,000 | 88,861,000 | 83,988,000 |
| Common Stock | 68,000 | 49,000 | 34,000 |
| Retained Earnings | -873,016,000 | -742,146,000 | -671,351,000 |
| Accumulated Other Comprehensive Income | 1,028,000 | 864,000 | 786,000 |
| Total Shareholders Equity | 336,501,000 | 266,323,000 | 96,368,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,540,000 | 464,000 | 396,000 |
| Share Based Compensation Expense | 36,740,000 | 12,057,000 | 14,177,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | -1,600,000 | 1,553,000 | 760,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -126,226,000 | 1,875,000 | -65,005,000 |
| Purchases Of Marketable Securities | 398,303,000 | 55,116,000 | 139,115,000 |
| Sales Of Marketable Securities | 183,000,000 | 55,284,000 | 124,000,000 |
| Acquisition Of Property Plant And Equipment | 4,052,000 | 3,483,000 | 2,150,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -219,355,000 | -3,315,000 | -17,265,000 |
| Tax Withholding For Share Based Compensation | 4,512,000 | 169,000 | 295,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 163,314,000 | 226,174,000 | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | 0 | 30,000,000 |
| Repayment Of Long Term Debt | 0 | 30,000,000 | 38,235,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 164,022,000 | 187,070,000 | -690,000 |
| Change In Cash | -181,559,000 | 185,630,000 | -82,960,000 |
| Cash At End Of Period | 99,704,000 | 281,263,000 | 95,633,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 0 | 1,405,000 | 2,600,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -2.32 | -1.82 | -2.74 |
| Price To Earnings Ratio | -3.2112 | -12.6978 | -1.2774 |
| Earnings Growth Rate | 27.4725 | -33.5766 | — |
| Price Earnings To Growth Ratio | -0.1169 | 0.3782 | — |
| Book Value Per Share | 5,977.1395 | 6.8456 | 2.5824 |
| Price To Book Ratio | 0.0012 | 3.3759 | 1.3553 |
| Ebitda | -129,316,000 | -69,084,000 | -98,669,000 |
| Enterprise Value | — | — | 75,451,500 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.42 |
| Capital Expenditures | 4,466,000 | 4,355,000 | 1,280,000 |
| Free Cash Flow | -130,692,000 | -2,480,000 | -66,285,000 |
| Return On Equity | -0.3889 | -0.2658 | -1.0611 |
| One Year Beta | 1.724 | 1.1028 | 0.9533 |
| Three Year Beta | 1.1336 | 1.1207 | 1.2113 |
| Five Year Beta | 1.2408 | 1.2543 | 1.2351 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Elston George | Chief Financial Officer | 2025-09-19 | 20,000 | D | 62,114 |
| Elston George | Chief Financial Officer | 2025-09-19 | 20,000 | A | 20,000 |
| Zaderej Karen L. | Director | 2025-07-11 | 2,000 | A | 38,500 |
| Zaderej Karen L. | Director | 2025-07-11 | 2,000 | D | 0 |
| Duker Jay S. | Director, President and CEO | 2025-07-10 | 16,667 | A | 17,653 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CWM, LLC | 2025-09-30 | 5,000 | 361 | 13.8504 |
| Farther Finance Advisors, LLC | 2025-09-30 | 8,572 | 602 | 14.2392 |
| Cyndeo Wealth Partners, LLC | 2025-09-30 | 316,555 | 22,230 | 14.24 |
| TOTH FINANCIAL ADVISORY CORP | 2025-09-30 | 28,495 | 2,001 | 14.2404 |
| VOYA INVESTMENT MANAGEMENT LLC | 2025-09-30 | 1,696,924 | 119,166 | 14.24 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 299 | 2,936.18 | 0.0012 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 48,682 | 478,057.24 | 0.0202 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 31,523 | 309,555.86 | 0.0235 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Total Market Index Fund | FZROX | 31,021 | 304,626.22 | 0.0011 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Extended Market Index Fund | FZIPX | 20,214 | 198,501.48 | 0.0108 |